Blood contains no fat (everything in plasma is water-soluble), so it is impossible for arteries to be blocked by fat.
Original statement
عليا الطلاق الدم ما فيه دهون ها والله الدم ما فيه دهون الدم كل اللي جوه البلازما بيدوب في الماء لا يدوب في الدهون خالص ما ينفعش الدهون تبقى في الدم ما ينفعش فما ينفعش حاجه اسمها سد الشريان بالدهون
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Blood contains no fat (everything in plasma is water-soluble), so it is impossible for arteries to be blocked by fat.
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live! السيليوليت (Open source)
- Published
- 11 October 2025
- Timestamp
- 2:25:57 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; wording may contain transcription errors; spoken live-stream language, context partly conversational.
- Claimed mechanism
Fats are insoluble in water and therefore cannot be in blood; the liver filters dietary fat.
- Claimed health effect
Fat cannot cause arterial blockage.
- Population concerned
Everyone.
- Geographic restriction by Elawady
none found
Diverging source versions
ده انت لو حاطط مكان الكبد سفنجه مش هتعدي الدهون دي
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- الذبحة الصدرية ؟! (Open source)
- Published
- 3 February 2025
- Timestamp
- 1:19:17 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; wording may contain transcription errors; spoken live-stream language, context partly conversational.
Scientific assessment
False – The statement contradicts the robust evidence.
Certainty of evidence: high – Further research is very unlikely to change the assessment.
1. What was claimed?
There is no fat in blood, so arteries cannot be clogged by fat.
2. What is demonstrably correct?
Fats are not water-soluble; this is exactly why the body packages them into lipoproteins (chylomicrons, VLDL, LDL, HDL) for transport in plasma. It is also correct that atherosclerosis is not simply fat 'sticking' like grease in a pipe; it is an inflammatory process in the artery wall.
3. What is wrong or exaggerated?
Blood plasma does carry large amounts of lipids (triglycerides and cholesterol) inside lipoproteins; these are measured in every lipid panel. LDL particles enter the artery wall and their cholesterol accumulates in atherosclerotic plaques; LDL is causal for atherosclerotic cardiovascular disease (I-FAT-02, 'unequivocally establishes'). The liver does not filter out dietary fat before it reaches the circulation: dietary fat is absorbed mainly via chylomicrons into the lymph and then the blood (general physiology, which he himself describes in other videos).
4. What remains unclear?
Nothing material.
5. Which studies support it?
None.
6. Which studies contradict it?
I-FAT-02 (EAS consensus: >200 cohorts, Mendelian randomisation and RCTs, >2 million participants); I-INTB-18 and I-FAT-110 (CTT: each 1 mmol/L LDL reduction lowers major vascular events by about 21-22%, at all ages).
7. What applies to Germany and Europe?
Universal; lipid measurement and LDL lowering are standard of care in Europe.
8. What is known about Egypt?
Same physiology applies.
9. What practical conclusion is appropriate?
This statement is false and could lead people to dismiss high cholesterol.
Assessment details
- Rationale for certainty of evidence
Lipid transport in blood via lipoproteins and the causal role of LDL in atherosclerosis are established by genetic, epidemiological and randomised evidence (I-FAT-02).
- Source quality
Elawady's own words (machine transcript), clearly stated. Notably, in other videos (e.g. RpO64V4Od7o, uj0_wxTtvA0) he himself explains chylomicrons, HDL and LDL as lipid carriers in blood.
- Regional transferability
Universal physiology.
- Individual exceptions
None.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Scientifically refuted – High-quality evidence shows the opposite, or the claim contradicts well-established physiology.
Research question: Does blood contain no fat, so that arteries cannot be blocked by fat?
Research question in detail (PECO)
- Population
- Humans
- Intervention or exposure
- Circulating lipoproteins (LDL)
- Comparison
- Lower LDL
- Geographic scope
- universal physiology
- Outcomes
- Presence of lipids in plasma
- Atherosclerotic cardiovascular events
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
No high-quality evidence supporting the claim was found.
What speaks against the claim?
Experts: LDL cholesterol causes artery disease
Ference BA et al.. Eur Heart J 2017 · PMID 28444290 · DOI 10.1093/eurheartj/ehx144 Guideline / position statementfull text, structured risk-of-bias assessmentEAS consensus: genetic, epidemiological and randomised evidence establishes LDL as a cause of ASCVD.
- Actual result
- ~22% fewer events per mmol/L LDL reduction (existing).
- Methodological quality
- high
- Relevance
- direct
- Limitations
- None material.
Statins: what 26 trials show
CTT Collaboration, Baigent C et al.. Lancet 2010 · PMID 21067804 · DOI 10.1016/S0140-6736(10)61350-5 Meta-analysisfull text, structured risk-of-bias assessmentCTT 2010: 26 RCTs, 170,000 participants; LDL lowering reduces major vascular events.
- Actual result
- RR 0.78 (0.76-0.80) per 1.0 mmol/L.
- Methodological quality
- high
- Relevance
- direct
- Limitations
- Drug trials.
Lowering LDL cholesterol prevents heart attacks and strokes at all ages
Cholesterol Treatment Trialists' Collaboration. Lancet 2019 · PMID 30712900 · DOI 10.1016/S0140-6736(18)31942-1 Meta-analysisabstract checkednewly addedCTT 2019: benefit of LDL lowering in all age groups.
- Actual result
- RR 0.79 (0.77-0.81) per 1.0 mmol/L.
- Methodological quality
- high
- Relevance
- direct
- Limitations
- Fewer data >75 without CVD.
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
Blood plasma carries large amounts of lipid inside lipoproteins; LDL is a proven cause of atherosclerosis.
Why some studies weigh more
Textbook physiology plus RCT and genetic evidence.
Is a causal relationship established? Yes, established LDL causality established by MR and RCTs.
Remaining uncertainty
None material.
Justified conclusion
The claim is false.
Does this depend on the country?
- General biological effects
- Universal physiology.
A regional difference that changes the conclusion is not supported by robust data.
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- ASCVD events per LDL reduction
- Starting level
- high (randomised trials)
- Reasons for upgrading
- dose-response
- consistency across MR and RCTs
- Result
- high
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Clinical guidelines and official statements checked
- ESC/EAS: 2019 ESC/EAS Guidelines for the management of dyslipidaemias (PMID 31504418) and 2025 Focused Update (PMID 40878289) (2019/2025) · Original publication could not be retrieved; content not used
- WHO: Saturated fatty acid and trans-fatty acid intake for adults and children: WHO guideline (2023) · Original publication
Landing page fetched (17 July 2023). Recommendations as registered in I-FAT-08: reduce saturated fat to 10% of energy (strong); replace with PUFA (strong), plant MUFA or fibre-rich carbohydrate (conditional).
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| Europe PMC | 26 October 2026 | ("cholesterol hypothesis" OR "LDL hypothesis" OR "diet-heart hypothesis") AND (critique OR questioned OR inconsistent OR "does not cause") | supporting evidence | 115 | |
| PubMed | 26 October 2026 | ("LDL cholesterol"[tiab] OR LDL-C[tiab]) AND (elderly[tiab] OR older[tiab]) AND mortality[tiab] AND (inverse*[tiab]) AND systematic review[pt] | supporting evidence | 1 | |
| PubMed | 26 October 2026 | Cholesterol Treatment Trialists[cn] AND older[ti] | contradicting evidence | 1 | |
| Europe PMC | 26 October 2026 | TITLE:"Efficacy and safety of statin therapy in older people" | contradicting evidence | 1 | |
| PubMed | 26 October 2026 | (ESC/EAS[ti] OR "ESC/EAS"[ti]) AND dyslipidaemia*[ti] AND guideline*[ti] | guidelines | 47 | |
| Europe PMC | 26 October 2026 | TITLE:"Focused Update" AND TITLE:"dyslipidaemias" | guidelines | 8 |
Open questions
None material.
How deeply was this checked?
4 linked studies: 2 checked in full text (2 of them with a structured risk-of-bias assessment), 2 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
In plain language
Fat does travel in the blood. Because fat does not mix with water, the body packs it into tiny particles called lipoproteins, such as LDL and HDL, which doctors measure in a cholesterol test. LDL particles can get into the wall of arteries, and the cholesterol they carry builds up in plaques. Many kinds of research, including genetic studies and drug trials, show that LDL causes artery disease. The statement that blood contains no fat is therefore wrong.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (4)
-
Experts: LDL cholesterol causes artery disease
Ference BA et al.. Eur Heart J 2017 · PMID 28444290 · DOI 10.1093/eurheartj/ehx144Guideline / position statementindependent cross-checkfull text, structured risk-of-bias assessment★ key studyGenetic studies, cohorts and drug trials agree: more LDL over time means more atherosclerosis.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Establish whether LDL is causal.
- How was the study done?
Consensus review of all evidence types.
- How many people, animals or samples were studied?
>2 million people.
- What was actually found?
LDL causes ASCVD.
- How large was the observed effect?
Log-linear dose-response.
- What do the results mean in everyday life?
High LDL is harmful.
- What are the study's limitations?
Expert consensus, not a systematic review; most panel members have ties to cholesterol-drug makers; absolute-benefit tables are projections.
- What does it say about Elawady's specific claim?
Contradicts claims that fat/cholesterol cannot harm arteries.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Effects of single foods.
-
Cochrane: eating less saturated fat reduces heart and stroke events
Hooper L et al.. Cochrane Database Syst Rev 2020 · PMID 32827219 · DOI 10.1002/14651858.CD011737.pub3Meta-analysisindependent cross-checkabstract checked★ key study17% fewer combined cardiovascular events (RR 0.83); no clear effect on deaths.
SFA reduction lowers cholesterol and CVD events.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Effect of less saturated fat.
- How was the study done?
Meta-analysis of 15 RCTs.
- How many people, animals or samples were studied?
56,675 adults.
- What was actually found?
Fewer CVD events; mortality unchanged.
- How large was the observed effect?
RR 0.83 (0.70-0.98); NNTB 56.
- What do the results mean in everyday life?
Cutting saturated fat helps the heart modestly.
- What are the study's limitations?
Old, heterogeneous trials.
- What does it say about Elawady's specific claim?
Contradicts 'ghee and butter don't affect arteries'.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Effect of a specific food like ghee.
-
Lowering LDL cholesterol prevents heart attacks and strokes at all ages
Cholesterol Treatment Trialists' Collaboration. Lancet 2019 · PMID 30712900 · DOI 10.1016/S0140-6736(18)31942-1Meta-analysisindependent cross-checkabstract checked★ key study21% fewer major vascular events per 1 mmol/L lower LDL, including older people.
Lowering blood LDL reduces atherosclerotic events.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test statins at different ages.
- How was the study done?
IPD meta-analysis of 28 RCTs.
- How many people, animals or samples were studied?
186,854 people.
- What was actually found?
Benefit at all ages.
- How large was the observed effect?
RR 0.79 per mmol/L.
- What do the results mean in everyday life?
High LDL matters even in older age.
- What are the study's limitations?
Drug trials.
- What does it say about Elawady's specific claim?
Contradicts the claim.
- Do the results apply to Germany and Europe?
Universal.
- What can explicitly not be concluded from this study?
Cannot directly test dietary cholesterol.
-
Statins: what 26 trials show
CTT Collaboration, Baigent C et al.. Lancet 2010 · PMID 21067804 · DOI 10.1016/S0140-6736(10)61350-5Meta-analysisindependent cross-checkfull text, structured risk-of-bias assessment★ key studyEach 1 mmol/L LDL reduction cut major vascular events by about a fifth and deaths by 10%, without more cancer.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Assess statin efficacy and safety
- How was the study done?
IPD meta-analysis
- How many people, animals or samples were studied?
about 170,000
- What was actually found?
Fewer heart attacks, strokes and deaths
- How large was the observed effect?
RR 0.78 per mmol/L for major vascular events; 2.8% vs 3.6% events per year (statin vs control)
- What do the results mean in everyday life?
Statins prevent heart attacks and strokes; the absolute gain is larger the higher the person's risk.
- What are the study's limitations?
Most trials industry-funded; data from 3 trials unavailable; only severe muscle damage (rhabdomyolysis) assessed
- What does it say about Elawady's specific claim?
Contradicts 'statins are forbidden'.
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Does not decide whether a specific low-risk person needs a statin.
No study in this group is marked as key.
Studies with mixed or unclear results (0)
No studies in this group.
Regional context
Germany / EU
Universal; lipid measurement and LDL lowering are standard of care in Europe.
Egypt
Same physiology applies.
What applies in my country?
General scientific assessment
False Blood carries fat in lipoproteins, and LDL cholesterol is a proven cause of artery disease; the claim is false.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.. Ference BA et al.. Eur Heart J 2017 · PMID 28444290 · DOI 10.1093/eurheartj/ehx144
- Reduction in saturated fat intake for cardiovascular disease.. Hooper L et al.. Cochrane Database Syst Rev 2020 · PMID 32827219 · DOI 10.1002/14651858.CD011737.pub3
- Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.. Cholesterol Treatment Trialists' Collaboration. Lancet 2019 · PMID 30712900 · DOI 10.1016/S0140-6736(18)31942-1
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.. CTT Collaboration, Baigent C et al.. Lancet 2010 · PMID 21067804 · DOI 10.1016/S0140-6736(10)61350-5